Therapy for Patients with Uncontrolled/Severe Asthma

What a Control-Based Asthma Management Strategy Looks Like

30 minutes

Media formats available:

Details

Presenters

Comments

Overview
Please note:This activity is no longer available for continuing education credit.
The introduction of biologics and updated understanding of asthma as a disease has changed our treatment approach to a more tailored, personalized strategy. This activity will take you through a pathophysiology-guided understanding of the various agents’ pharmacology. It will dive into a side-by-side exploration of safety and efficacy data for new and emerging treatments for asthma, reinforced by clinical case scenarios, expert commentary, interactive tools, and downloadable resources—all packaged and delivered in a visually impactful infographic design.
Provider
Faculty
Reynold A. Panettieri, Jr, MD
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University
New Brunswick, NJ
Emeritus Professor, Medicine,
University of Pennsylvania
Philadelphia, PA
Conflict of Interest Policy/Disclosure Statement
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Reynold A. Panettieri, Jr, MD, has affiliations with AstraZeneca, Boehringer-Ingelheim, Novartis, RIFM, Teva Pharmaceuticals Industries Ltd., Theravance Biopharma (Consulting Fees); AstraZeneca, Boehringer – Ingelheim, Genentech, Novartis, Teva Pharmaceutical Industries Ltd., Sanofi (Commercial Interests); AstraZeneca, Bristol Myers Squibb, Genentech, Gilead Sciences, Inc., MedImmune, OncoArendi Therapeutics, RIFM, Sanofi, Theratrophix LLC, Vertex (Contracted Research)
Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.
Target Audience
The target audience for this activity is pulmonary and allergy/immunology providers including physicians, nurse practitioners, and physician assistants who manage patients with asthma.
Learning Objectives
1. Identify patients with poorly controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics.
2. Incorporate new and emerging targeted biologics into the management of patients with severe or poorly controlled asthma when appropriate.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Media: Internet
Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
How to Receive Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email inquiries@pimed.com.
Publication Dates
Release Date:03/01/2019
Expiration Date: This activity is no longer available for continuing education credit.

Presenters

Reynold A. Panettieri, Jr., MD

Facebook Comments

Recommended

Details

Presenters

Comments

Overview
Please note:This activity is no longer available for continuing education credit.
The introduction of biologics and updated understanding of asthma as a disease has changed our treatment approach to a more tailored, personalized strategy. This activity will take you through a pathophysiology-guided understanding of the various agents’ pharmacology. It will dive into a side-by-side exploration of safety and efficacy data for new and emerging treatments for asthma, reinforced by clinical case scenarios, expert commentary, interactive tools, and downloadable resources—all packaged and delivered in a visually impactful infographic design.
Provider
Faculty
Reynold A. Panettieri, Jr, MD
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University
New Brunswick, NJ
Emeritus Professor, Medicine,
University of Pennsylvania
Philadelphia, PA
Conflict of Interest Policy/Disclosure Statement
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Reynold A. Panettieri, Jr, MD, has affiliations with AstraZeneca, Boehringer-Ingelheim, Novartis, RIFM, Teva Pharmaceuticals Industries Ltd., Theravance Biopharma (Consulting Fees); AstraZeneca, Boehringer – Ingelheim, Genentech, Novartis, Teva Pharmaceutical Industries Ltd., Sanofi (Commercial Interests); AstraZeneca, Bristol Myers Squibb, Genentech, Gilead Sciences, Inc., MedImmune, OncoArendi Therapeutics, RIFM, Sanofi, Theratrophix LLC, Vertex (Contracted Research)
Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.
Target Audience
The target audience for this activity is pulmonary and allergy/immunology providers including physicians, nurse practitioners, and physician assistants who manage patients with asthma.
Learning Objectives
1. Identify patients with poorly controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics.
2. Incorporate new and emerging targeted biologics into the management of patients with severe or poorly controlled asthma when appropriate.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Media: Internet
Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
How to Receive Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email inquiries@pimed.com.
Publication Dates
Release Date:03/01/2019
Expiration Date: This activity is no longer available for continuing education credit.

Presenters

Reynold A. Panettieri, Jr., MD

CME: Escalating Therapy for Patients with Uncontrolled/Severe Asthma

What a Control-Based Asthma Management Strategy Looks Like

Provider

Faculty

Conflict of Interest Policy/Disclosure Statement

Target Audience

Learning Objectives

Joint Accreditation Statement

Commercial Support

Disclaimer

How to Receive Credit

Publication Dates

Facebook Comments

Recommended

Provider

Faculty

Conflict of Interest Policy/Disclosure Statement

Target Audience

Learning Objectives

Joint Accreditation Statement

Commercial Support

Disclaimer

How to Receive Credit

Publication Dates

Facebook Comments

Segment Chapters

Playlist:

Recommended

Related

How to ID Patients with Difficult-to-Control Asthma

Directory of Drug Assistance Programs

Health Insurance for Patients with Asthma by AAFA

Biologic Therapy Interactive Tool

Facebook Comments

Recommended

Related

How to ID Patients with Difficult-to-Control Asthma

Directory of Drug Assistance Programs

Health Insurance for Patients with Asthma by AAFA

Biologic Therapy Interactive Tool

Facebook Comments

Title

Share on ReachMD

Segment Chapters

Playlist:

Recommended

Get a Dose of ReachMD in Your Inbox and Practice Smarter Medicine